用生物信息学和机器学习来确定阿尔茨海默病治疗的治疗点
ZhanQiang Xie1, YongLi Situ2, Li Deng2
1Department of Thoracic Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, China.
Scientific reports
|January 31, 2025
概括
这项研究确定了包括PLCB1在内的五个关键基因,作为阿尔茨海默病 (AD) 的潜在治疗标. PLCB1显示出高诊断价值,指导选择诺斯卡,PX-316和TAK-901作为有前途的AD药物候选者.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 计算生物学 计算生物学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,有效治疗方法有限.
- 确定新的治疗点和诊断生物标志物对于推进AD治疗策略至关重要.
研究的目的:
- 通过综合生物信息学和机器学习方法,确定阿尔茨海默病 (AD) 的潜在治疗点.
- 发现新的诊断生物标志物和潜在的候选药物用于AD治疗.
主要方法:
- 不同基因表达分析,加权基因共同表达网络分析 (WGCNA),Mfuzz聚类和单细胞RNA测序 (scRNA-seq).
- 使用了机器学习算法,包括LASSO回归,支持矢量机器-递归特征消除 (SVM-RFE) 和随机森林.
- 确定枢纽基因和与临床AD参数 (布拉克阶段,神经元表达) 的相关性分析.
主要成果:
- 五个枢纽基因 (PLCB1,NDUFAB1,KRAS,ATP2A2,CALM3) 被确定与AD有显著的关联.
- PLCB1显示了AD的最高诊断值,并且与布拉克阶段和神经元表达有显著的相关性.
- 诺斯卡平,PX-316和TAK-901被确定为针对AD的PLCB1的潜在治疗药物.
结论:
- 该研究提出了一个强大的生物信息学和机器学习框架,用于发现AD治疗目标和诊断模型.
- 现在,PLCB1成为了AD诊断的关键基因,也是新型治疗干预的潜在目标.
- 已识别的候选药物为未来的阿尔茨海默病药物开发提供了有希望的途径.
相关概念视频
Alzheimer's Disease: Treatment
158
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
158
Alzheimer's Disease: Overview
437
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
437


